Background: Central obesity is a risk factor for cardiovascular and metabolic disorders including diabetes, hypertension and dyslipidemia. Index of central obesity (ICO) , defined as ratio of waist circumference and height, has been earlier proposed as a screening tool for central obesity and metabolic syndrome. We report the prevalence of self-reported central obesity based on ICO in a nationwide community screening program from data collected by the Research Society for the Study of Diabetes in India (RSSDI) as part of the Defeat Diabetes Campaign.

Methodology: Data collected from the One Nation, One Day, One Million Tests campaign by RSSDI was retrospectively analyzed. A data of 105481 adults was included in the analysis (69483 were males and 35956 females) . ICO (calculated from self-reported waist size & height) cutoff of 0.5 was used to estimate the prevalence of central obesity in the Indian population.

Results: 69.3% (n=73072) of the overall cohort was found to be having central obesity, prevalence being slightly higher among females (75.1%) compared to males (66.3%) . Prevalence of central obesity was higher among diabetic subjects (77.8%) compared to the nondiabetes population (64.6%) . Prevalence of central obesity was higher among females with diabetes (81.5%) compared to males (75.9%) . Prevalence of central obesity was 60.8% and 71.8% in males and females without diabetes respectively.

Conclusions: Central obesity is highly prevalent in the Indian population, with prevalence being slightly higher among females compared to males and among people living with diabetes when compared to nondiabetes subjects. As central obesity is a known risk factor for CVD and Metabolic disorders - strategies and interventions directed to address central obesity may be developed and implemented to prevent the future incidence of CVD and Metabolic disorders including diabetes. ICO is a simple screening tool in population dense and resource limited settings.


B.D.Saboo: None. S.Chittawar: None. A.Nanditha: None. R.M.Parikh: None. A.Gupta: Speaker's Bureau; Lupin Pharmaceuticals, Inc., Medtronic, Novartis AG, Novo Nordisk, Sanofi. V.K.Ch: None. B.M.Makkar: None. S.Agarwal: Speaker's Bureau; Novo Nordisk, Roche Diabetes Care, Sanofi, USV Private Limited. P.M.Chawla: Speaker's Bureau; Biocon, Boehringer Ingelheim International GmbH, Eris Lifesciences Ltd., Novo Nordisk, Sanofi. R.R.Kovil: None. S.Bhattacharyya: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at